In a report released today, Gaurav Maini from LifeSci Capital maintained a Buy rating on Tenax Therapeutics, with a price target of $35.00.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Maini is a 4-star analyst with an average return of 30.8% and a 100.00% success rate. Maini covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Tectonic Therapeutic, and Inhibikase Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenax Therapeutics with a $37.40 average price target.
Based on Tenax Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.72 million. In comparison, last year the company had a GAAP net loss of $10.41 million
